Melody.education: Educational programs on Nonalcoholic Steatohepatitis (NASH) and Nonalcoholic Fatty Liver Disease (NAFLD)

Prof Michael Trauner presents: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: Welcome and Introduction

Prof Jörn Schattenberg presents: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: NASH: A Growing Unmet Therapeutic Need

Prof Meena Bansal, MD presents: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: The Underestimated Importance of Thyroid Hormone Pathway in the Pathophysiology of NASH

Prof Michael Trauner presents: Emerging Role of the Hepatic Thyroid Hormone Pathway in the Pathophysiology of NASH as presented at EASL ‘23: Closing

Scott Isaacs, MD, FACE, FACP and Barton Isaac, PharmD present: NASH Patient Identification, Referral and Management in Endocrinology and Hepatology Practices

Keith Miller, PhD presents: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Introduction

Christina Hanson, MS, FNP presents: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Definitions and Epidemiology; Pathophysiology; Natural History of the Disease; Morbidity and Mortality

Ann Moore, FNP-C presents: Disease Overview of Nonalcoholic Steatohepatitis (NASH): The Active, Progressive Form of Nonalcoholic Fatty Liver Disease (NAFLD): Identifying Risk Factors; Patient Identification; Patient Perspective

Prof Quentin M. Anstee presents Part 1: Identifying, Managing, and Treating Patients With NASH and Significant Fibrosis - Current Practice and Future Perspectives as presented at EASL 2022

Jörn M. Schattenberg, MD presents Part 2: Identifying, Managing, and Treating Patients With NASH and Significant Fibrosis - Current Practice and Future Perspectives as presented at EASL 2022

Stephen A. Harrison, MD, FACP, FAASLD presents Part 3: Identifying, Managing, and Treating Patients With NASH and Significant Fibrosis - Current Practice and Future Perspectives as presented at EASL 2022

Prof Quentin M. Anstee, Jörn M. Schattenberg, MD, and Stephen A. Harrison, MD, FACP, FAASLD present Part 4: Q&A - Identifying, Managing, and Treating Patients With NASH and Significant Fibrosis - Current Practice and Future Perspectives as presented at EASL 2022: Q&A

Mazen Noureddin, MD, MHSc presents Part 1: Emerging Concepts in Non-Alcoholic Steatohepatitis (NASH): Disease Education Program as presented at CLDF 2022

Marcelo Kugelmas, MD, FAASLD, FACP presents Part 2: Emerging Concepts in Non-Alcoholic Steatohepatitis (NASH): Disease Education Program as presented at CLDF 2022

Mazen Noureddin, MD, MHSc, and Marcelo Kugelmas, MD, FAASLD, FACP present Part 3: Emerging Concepts in Non-Alcoholic Steatohepatitis (NASH): Disease Education Program: Q&A as presented at CLDF 2022

Scott L. Friedman, MD and Wayne Eskridge present: Patient Video Series in Partnership with the Fatty Liver Foundation: Fatty Liver Foundation Development

Scott L. Friedman, MD and Wayne Eskridge present Part 2: Patient Video Series in Partnership with the Fatty Liver Foundation: Advice for Patients with Recent Diagnosis of NASH with Fibrosis

Scott L. Friedman, MD and Wayne Eskridge present Part 3: Patient Video Series in Partnership with the Fatty Liver Foundation: After Diagnosis: What Happens Now?